Fennec Pharmaceuticals Inc. (FENC)
$6.94
-0.15 (-2.12%)
Rating:
Recommendation:
Buy
| Symbol | FENC |
|---|---|
| Price | $6.94 |
| Beta | 0.090 |
| Volume Avg. | 0.03M |
| Market Cap | 180.713M |
| Shares () | - |
| 52 Week Range | 3.822-10.078 |
| 1y Target Est | - |
| DCF Unlevered | FENC DCF -> | |
|---|---|---|
| DCF Levered | FENC LDCF -> | |
| ROE | -217.00% | Strong Sell |
| ROA | -194.62% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 82.27% | Buy |
| P/E | - | |
| P/B | 21.17 | Strong Buy |
Latest FENC news
About
Download (Excel)Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.